newsfilter
← Latest News
Business Wire·

Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform

Autolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical